ArticleOphthalmology science
Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-Resistant
Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- Antibiotic resistance mechanisms and global resistance patterns of Pseudomonas aeruginosa in microbial keratitis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Enhanced Efficacy of Cefiderocol With PolyTrim Combination Therapy in a Rabbit Model of Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis.Investigative ophthalmology & visual science · 2026Article
- Cefiderocol Is Effective In Vitro Against Numerous Gram-Negative Species Isolated from Keratitis Patients.Antibiotics (Basel, Switzerland) · 2026Article
- Could a Preservative Have Prevented the Extremely-Drug ResistantCurrent eye research · 2026Article
- Emerging Ocular Pathogen Resistance and Clinically Used Solutions: A Problem That Is More than Meets the Eye.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak.Investigative ophthalmology & visual science · 2025Article
- Combination Therapy of Cefiderocol and Polymyxin B Against Pseudomonas aeruginosa Keratitis Isolates In Vitro.Translational vision science & technology · 2025Article
- Developing a Pseudomonas aeruginosa keratitis model in Swiss albino mice for clinical assessment.The Indian journal of medical research · 2025Article
- Efficacy of Cefiderocol Against Endophthalmitis Isolates.Antibiotics (Basel, Switzerland) · 2024Article
- The Efficacy of Topical Cefiderocol Treatment of Experimental Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Genome sequence generated by hybrid Nanopore-Illumina assembly of an extensively drug-resistantMicrobiology resource announcements · 2024Article
Corrections and comments
- Update of
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Purpose: To test cefiderocol, a siderophore-cephalosporin antibiotic for topical monotherapy treatment of experimental extensively drug-resistant (XDR) Design: Preclinical study. Subjects and Controls: Deidentified Methods Intervention or Testing: Cefiderocol antibacterial activity against Main Outcome Measures: Minimum inhibitory concentration analysis for susceptibility, graded tests for ocular toxicity/tolerability, colony-forming unit (CFU) analysis for bacterial burden, corneal cefiderocol concentrations. Results: One hundred percent of Conclusions: These results demonstrate that cefiderocol is well tolerated on rabbit corneas and is effective against Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.